Research programme: kinase inhibitors - LocusAlternative Names: LP-1890; LP-590
Latest Information Update: 01 Sep 2009
At a glance
- Originator Locus Pharmaceuticals
- Class Ethers; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors; Proto oncogene protein c ret inhibitors; Raf kinase inhibitors; TIE 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer; Inflammation